1. Ageno W, Squizzato A, Garcia D et al. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006; 32: 651–658.
2. Kearon C, Julian JA, Kovacs MJ et al. ELATE Investigators. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008; 112: 4432–4436.
3. Zöller B, García de Frutos P, Hillarp A et al. Thrombophilia as a multigenic disease. Haematologica 1999; 84: 59–70.
4. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–67.
5. den HeijerM, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759–762.
6. Heijboer H, Brandjes DP, Büller HR et al. Deficiencies of coagulation‑inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512–1516.
7. Koster T, Rosendaal FR, de Ronde H et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Trombophilia Study. Lancet 1993; 342: 1503–1506.
8. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991–996.
9. Pabinger I, Brücker S, Kyrle PA et al. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 1992; 3: 547–553.
10. Tait RC, Walker ID, Perry DJ et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106–112.
11. Tait RC, Walker ID, Reitsma PH et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87–93.
12. Nordström M, Lindblad B, Bergqvist D et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155–160.
13. Martinelli I, Mannucci PM, De Stefano V et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353–2358.
14. Simioni P, Sanson BJ, Prandoni P et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198–202.
15. Middeldorp S, Henkens CM, Koopman MM et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 15–20.
16. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3‘-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–3703.
17. Blom JW, Doggen CJ, Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–722.
18. Koster T, Blann AD, Briët E et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152–155.
19. Kraaijenhagen RA, in’t Anker PS, Koopman MM et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5–9.
20. van Hylckama Vlieg A, van der Linden IK, Bertina RM et al. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678–3682.
21. Meijers JCM. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Eng J Med 2000; 342: 696–701.
22. den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis: a meta‑analysis. Thromb Haemost 1998; 80: 874–877.
23. Wahl DG, Guillemin F, de Maistre E et al. Meta‑analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15–22.
24. Christiaens L. Idiopathic venous thromboembolic disease. Risk factors for recurrence in 2006. Arch Mal Coeur Vaiss 2007; 100: 133–138.
25. Linnemann B, Zgouras D, Schindewolf M et al. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagul Fibrinolysis 2008; 19: 159–165.
26. Dalen JE. Should patients with venous thromboembolism be screened for thrombophilia? Am J Med 2008; 121: 458–463.
27. Stevenson MD, Rawdin A, Papaioannou D. Thrombophilia testing in people with venous thromboembolism: systematic review and cost‑effectiveness analysis. Health Technol Assess 2009; 13: 1–91.
28. Sternitzky R, Hochauf S, Schellong SM. Secondary prophylaxis of venous thromboembolism. Hamostaseologie 2007; 27: 32–40.
29. Prandoni P, Noventa F, Ghirarduzzi A et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199–205.
30. Baglin T, Luddington R, Brown K et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523–526.
31. Palareti G, Legnani C, Cosmi B et al. Predictive value of D‑dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313–318.
32. Lindmarker P, Schulman S, Sten-Linder M et al. The risk of recurrent venous thromboembolism in carriers and non‑carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81: 684–689.
33. Simioni P, Prandoni P, Lensing AW et al. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Eng J Med 1997; 336: 399–403.
34. Ridker PM. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800–2802.
35. Eichinger S, Weltermann A, Mannhalter C et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002; 162: 2357–2360.
36. Kovac M, Mikovic D, Antonijevic N et al. FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population. J Thromb Thrombolysis 2008; 25: 284–287.
37. Marchiori A, Mosena L, Prins MH et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107–1114.
38. Eichinger S, Minar E, Hirschl M et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999; 81: 14–17.
39. De Stefano V, Martinelli I, Mannucci PM et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001; 113: 630–635.
40. Miles JS, Miletich JP, Goldhaber SZ et al. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001; 37: 215–218.
41. Eichinger S, Stümpflen A, Hirschl M et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566–569.
42. den Heijer M, Blom HJ, Gerrits WB et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882–885.
43. Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Eng J Med 2000; 343: 457–462.
44. Legnani C, Cini M, Cosmi B et al. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica 2004; 89: 1347–1351.
45. Eischer L, Gartner V, Schulman S et al. For the AUREC-FVIII investigators (as listed in acknowledgements). 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Ann Hematol 2008. [Epub ahead of print].
46. Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost 1996; 75: 859.
47. Rance A, Emmerich J, Fiessinger JN. Anticardiolipin antibodies and recurrent thromboembolism. Thromb Haemost 1997; 77: 221–222.
48. Schulman S, Svenungsson E, Grangvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332–338.
49. Bounameaux H, Perrier A. Duration of anticoagulation therapy for venous thromboembolism. Hematology Am Soc Hematol Educ Program 2008; 2008: 252–258.
50. Cosmi B, Legnani C, Cini M et al. D‑dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Res 2008; 122: 610–617.
51. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl 3): 338S–400S.
52. White RH, Zhou H, Romano PS. Incidence of symptomatic venous tromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90: 446–455.
53. Bates SM, Greer IA, Pabinger I et al. American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl 6): 844S–886S.
54. Heit JA, Melton LJ 3rd, Lohse CM et al. Incidence of venous tromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001; 76: 1102–1110.
55. Heit JA, O’Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population‑based study. Arch Intern Med 2002; 162: 1245–1248.
56. Alikhan R, Cohen AT, Combe S et al. Risk factors for venous tromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963–968.
57. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population‑based case control study. Arch Intern Med 2000; 160: 809–815.
58. Heit JA, Petterson TM, Bailey KR et al. The influence of tumor site on venous tromboembolism risk among cancer patients: a population‑based study (Abstract 2596). Blood 2004; 104: 711a.
59. Levitan N, Dowlati A, Remick SC. Rates of initial and recurrent tromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285–291.
60. Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004; 11: 192–197.
61. Kearon C, Gent M, Hirsh J et al. A comparsion of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous tromboembolism. N Engl J Med 1999; 340: 901–907.
62. Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Eng J Med 2001; 345: 165–169.
63. Baglin T, Luddington R, Brown K et al. Incidence of recurrent venous tromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523–526.
64. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769–774.
65. Cushman M, Tsai AW, White RH et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19–25.
66. Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population‑based cohort study. Arch Intern Med 2000; 160: 761–768.
67. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous tromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–3488.
68. Prandoni P, Lensing AW, Cogo A et al. The long‑term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1–7.
69. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis 2008; 25: 37–44.
70. Piovella F, Crippa L, Barone M et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002; 87: 515–522.
71. Prandoni P, Lensing AW, Prins MH et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955–960.
72. Eichinger S, Minar E, Bialonczyk C et al. D‑dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071–1074.
73. Verhovsek M, Douketis JD, Yi Q et al. Systematic review: D‑dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149: 481–490.
74. Palareti G, Cosmi B, Legnani C et al. PROLONG Investigators. D‑dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780–1789.
75. Rey E, Kahn SR, David M et al. Thrombophilic disorders and fetal loss: a meta‑analysis. Lancet 2003; 361: 901–908.
76. Gris JC, Mercier E, Quéré I et al. Low-molecular-weight heparin versus low‑dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695–3699.
77. Clark P, Brennand J, Conkie JA et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166–1170.
78. Stirling Y, Woolf L, North WR et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176–182.
79. Bonnar J, McNicol GP, Douglas AS. Fibrinolytic enzyme system and pregnancy. Br Med J 1969; 3: 387–389.
80. Beller FK, Ebert C. The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. Eur J Obstet Gynecol Reprod Biol 1982; 13: 177–197.
81. McColl MD, Ramsay JE, Tait RC et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183–1188.
82. Lindqvist P, Dahlbäck B, Marsˆál K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595–599.
83. Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001; 86: 104–111.
84. Martinelli I, Legnani C, Bucciarelli P et al. Risk of pregnancy‑related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86: 800–803.
85. Brill-Edwards P, Ginsberg JS, Gent M et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343: 1439–1444.
86. Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473–478.
87. Pomp ER, Lenselink AM, Rosendaal FR et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632–637.
88. Martinelli I, De Stefano V, Taioli E et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87: 791–795.
89. Blanco-Molina A, Trujillo-Santos J, Criado J et al. RIETE Investigators. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost 2007; 97: 186–190.
90. Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high‑risk situations: systematic review and cost‑effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006; 10: 1–110.
91. Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Eng J Med 2000; 342: 374–380.
92. Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77–85.
93. Hallak M, Senderowicz J, Cassel A et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynec 1997; 176: 889–893.
94. Hirsch DR, Mikkola KM, Marks PW et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996; 131: 1145–1148.
95. Lensen RP, Bertina RM, de Ronde H et al. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000; 83: 817–821.
96. Meglic L, Stegnar M, Milanez T et al. Factor V Leiden, prothrombin 20210G-A, methylentetrahydrofolate reductase 677C-T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy‑related venous tromboembolism. Eur J Obstet Gynecol Reprod Biol 2003; 111: 157–163.
97. Ogunyemi D, Cuellar F, Ku W et al. Association between inherited trombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous tromboembolism in pregnancy. Am J Perinatol 2003; 20: 17–24.
98. Nelen WL, Blom HJ, Steegers EA et al. Hyperhomocysteinaemia and recurrent early pregnancy loss: a meta analysis. Fertil Steril 2000; 74: 1196–1199.
99. Lindqvist PG, Svensson PJ, Marsaál K et al. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532–537.
100. Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ 1998; 316: 95–99.
101. Robertson L, Wu O, Langhorne P et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171–196.
102. Bauersachs RM, Dudenhausen J, Faridi A et al. EThIG Investigators. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98: 1237–1245.
103. Lindhoff-Last E, Luxembourg B. Evidence‑based indications for thrombophilia screening. Vasa 2008; 37: 19–30.
104. Simioni P. Who should be tested for thrombophilia? Curr Opin Hematol 2006; 13: 337–343.
105. Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden: cost‑effectiveness analysis. Thromb Haemost 2000; 84: 752–757.
106. DiNisio M, Peters LW, Middeldorp S. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. Protocol for a Cochrane Review. The Cochrane Library 2004.
107. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications – No. J Thromb Haemost 2003; 1: 2073–2074.